Domača stranATYR • NASDAQ
add
aTyr Pharma Inc
Prejšnji trg. dan.
3,53 $
Dnevni razpon
3,28 $ - 3,50 $
Letni razpon
1,42 $ - 4,22 $
Tržna kapitalizacija
280,79 mio. USD
Povprečni obseg
857,89 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 3,34 mio. | 25,93 % |
Čisti dohodek | −17,26 mio. | −52,20 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | −0,23 | −15,00 % |
EBITDA | −17,96 mio. | −44,42 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 65,99 mio. | −35,39 % |
Skupna sredstva | 91,62 mio. | −26,75 % |
Skupne obveznosti | 26,48 mio. | −1,45 % |
Celoten lastniški kapital | 65,14 mio. | — |
Shares outstanding | 83,94 mio. | — |
Razmerje P/B | 4,10 | — |
Donosnost sredstev | −45,92 % | — |
Donosnost kapitala | −52,14 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −17,26 mio. | −52,20 % |
Denar iz dejavnosti | −13,16 mio. | −37,65 % |
Denar iz naložb | 17,95 mio. | 309,45 % |
Denar iz financiranja | −105,00 tis. | −103,91 % |
Neto sprememba denarnih sredstev | 4,68 mio. | 287,77 % |
Prost denarni tok | −6,49 mio. | −12,66 % |
Vizitka
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Datum ustanovitve
1. jan. 2005
Spletno mesto
Zaposleni
58
